Prediction of neuroblastoma cell response to treatment with
natural or synthetic retinoids using selected protein
biomarkers

J 2019

Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers

DOBROTKOVÁ, Viera, Petr CHLAPEK, Marta JEŽOVÁ, Kateřina ADÁMKOVÁ, Pavel MAZÁNEK et. al.

Basic information

Original name

Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers

Authors

DOBROTKOVÁ, Viera (703 Slovakia, belonging to the institution), Petr CHLAPEK (203 Czech Republic, belonging to the institution), Marta JEŽOVÁ (203 Czech Republic, belonging to the institution), Kateřina ADÁMKOVÁ (203 Czech Republic, belonging to the institution), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution) and Renata VESELSKÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

PLOS ONE, San Francisco, Public Library of Science, 2019, 1932-6203

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.740

RIV identification code

RIV/00216224:14310/19:00108499

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1371/journal.pone.0218269

UT WoS

000471234500064

Keywords in English

Neuroblastoma; induced differentiation; retinoids; retinoic acid; bexarotene; fenretinide; biomarkers

Abstract

V originále

Although the administration of retinoids represents an important part of treatment for children suffering from high-risk neuroblastomas, approximately 50% of these patients do not respond to this therapy or develop resistance to retinoids during treatment. Our study focused on the comparative analysis of the expression of five genes and corresponding proteins (DDX39A, HMGA1, HMGA2, HOXC9 and PBX1) that have recently been discussed as possible predictive biomarkers of clinical response to retinoid differentiation therapy. Expression of these five candidate biomarkers was evaluated at both the mRNA and protein level in the same subset of 8 neuroblastoma cell lines after treatment with natural or synthetic retinoids. We found that the cell lines that were HMGA2-positive and/or HOXC9-negative have a reduced sensitivity to retinoids. Furthermore, the experiments revealed that the retinoid-sensitive cell lines showed a uniform pattern of change after treatment with both natural and sensitive retinoids: increased DDX39A and decreased PBX1 protein levels. Our results showed that in NBL cells, these putative protein biomarkers are associated with sensitivity or resistance to retinoids, and their endogenous or induced expression can distinguish between these two phenotypes.

Links

MUNI/A/1586/2018, interní kód MU

Name: Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medecine" a "N-of-1 clinical trials" (Acronym: Personalizovaná léčba v dětské onkologii)

Investor: Masaryk University, Category A

NV15-34621A, research and development project

Name: Kandidátní biomarkery rezistence k retinoidům u dětí s vysoce rizikovými neuroblastomy

Citovat

DOBROTKOVÁ, Viera, Petr CHLAPEK, Marta JEŽOVÁ, Kateřina ADÁMKOVÁ, Pavel MAZÁNEK, Jaroslav ŠTĚRBA and Renata VESELSKÁ. Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers. PLOS ONE. San Francisco: Public Library of Science, 2019, vol. 14, No 6, p. 1-18. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0218269.

@article{1546080,
   author = {Dobrotková, Viera and Chlapek, Petr and Ježová, Marta and Adámková, Kateřina and Mazánek, Pavel and Štěrba, Jaroslav and Veselská, Renata},
   article_location = {San Francisco},
   article_number = {6},
   doi = {http://dx.doi.org/10.1371/journal.pone.0218269},
   keywords = {Neuroblastoma; induced differentiation; retinoids; retinoic acid; bexarotene; fenretinide; biomarkers},
   language = {eng},
   issn = {1932-6203},
   journal = {PLOS ONE},
   title = {Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers},
   url = {https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218269},
   volume = {14},
   year = {2019}
}

TY  - JOUR
ID  - 1546080
AU  - Dobrotková, Viera - Chlapek, Petr - Ježová, Marta - Adámková, Kateřina - Mazánek, Pavel - Štěrba, Jaroslav - Veselská, Renata
PY  - 2019
TI  - Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers
JF  - PLOS ONE
VL  - 14
IS  - 6
SP  - 1-18
EP  - 1-18
PB  - Public Library of Science
SN  - 19326203
KW  - Neuroblastoma
KW  - induced differentiation
KW  - retinoids
KW  - retinoic acid
KW  - bexarotene
KW  - fenretinide
KW  - biomarkers
UR  - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218269
L2  - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218269
N2  - Although the administration of retinoids represents an important part of treatment for children suffering from high-risk neuroblastomas, approximately 50% of these patients do not respond to this therapy or develop resistance to retinoids during treatment. Our study focused on the comparative analysis of the expression of five genes and corresponding proteins (DDX39A, HMGA1, HMGA2, HOXC9 and PBX1) that have recently been discussed as possible predictive biomarkers of clinical response to retinoid differentiation therapy. Expression of these five candidate biomarkers was evaluated at both the mRNA and protein level in the same subset of 8 neuroblastoma cell lines after treatment with natural or synthetic retinoids. We found that the cell lines that were HMGA2-positive and/or HOXC9-negative have a reduced sensitivity to retinoids. Furthermore, the experiments revealed that the retinoid-sensitive cell lines showed a uniform pattern of change after treatment with both natural and sensitive retinoids: increased DDX39A and decreased PBX1 protein levels. Our results showed that in NBL cells, these putative protein biomarkers are associated with sensitivity or resistance to retinoids, and their endogenous or induced expression can distinguish between these two phenotypes.
ER  -

DOBROTKOVÁ, Viera, Petr CHLAPEK, Marta JEŽOVÁ, Kateřina ADÁMKOVÁ, Pavel MAZÁNEK, Jaroslav ŠTĚRBA and Renata VESELSKÁ. Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers. \textit{PLOS ONE}. San Francisco: Public Library of Science, 2019, vol.~14, No~6, p.~1-18. ISSN~1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0218269.

Detailed Information on Publication Record